Innovative Licensing and Access Pathway (ILAP)

AI Summary

The Innovative Licensing and Access Pathway (ILAP) is a collaborative initiative launched by the UK Medicines and Healthcare products Regulatory Agency (MHRA) in partnership with the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and other UK health organizations. This guidance document outlines a regulatory framework designed to accelerate patient access to transformative medicines and drug-device combinations by providing a single platform for integrated, sustained collaboration between developers and the UK healthcare system. The program is open to both commercial and non-commercial developers globally. Eligibility requires a therapeutic focus and preliminary evidence of safety in humans before confirmatory trials begin. The pathway begins with the Innovation Passport, which serves as the mandatory entry point. Successful applicants then work with a specialist team to create a Target Development Profile (TDP). This living roadmap identifies regulatory and developmental challenges, streamlines evidence generation, and coordinates market access and adoption strategies across the NHS. Key benefits include prioritized access to regulatory services, parallel data evaluation by multiple agencies, and early engagement with patients and healthcare providers. By aligning evidence requirements early in development, ILAP reduces the time and costs associated with independent interactions and de-risks the product pipeline. Interested developers must review the eligibility criteria and submit an application through the ILAP registration portal to begin the process.